443 related articles for article (PubMed ID: 23899063)
41. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer.
Honkoop AH; Luykx-de Bakker SA; Hoekman K; Meyer S; Meyer OW; van Groeningen CJ; van Diest PJ; Boven E; van der Wall E; Giaccone G; Wagstaff J; Pinedo HM
Oncologist; 1999; 4(2):106-11. PubMed ID: 10337380
[TBL] [Abstract][Full Text] [Related]
42. A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN).
Chollet P; Abrial C; Durando X; Thivat E; Tacca O; Mouret-Reynier MA; Leheurteur M; Kwiatkowski F; Dauplat J; Penault-Llorca F
Cancer J; 2008; 14(2):128-32. PubMed ID: 18391619
[TBL] [Abstract][Full Text] [Related]
43. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM
Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851
[TBL] [Abstract][Full Text] [Related]
44. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
45. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
[TBL] [Abstract][Full Text] [Related]
46. [Evaluation of breast cancer treatment at a tertiary-level institution with Popular Health Insurance in Mexico].
Arce-Salinas C; Lara-Medina FU; Alvarado-Miranda A; Castañeda-Soto N; Bargalló-Rocha E; Ramírez-Ugalde MT; Pérez-Sánchez V; Rivera L; Gambo-Vignole C; Santamaría-Galicia J; Nieves-Casas RI; Morán-Muñoz H; Mohar-Betancourt A
Rev Invest Clin; 2012; 64(1):9-16. PubMed ID: 22690524
[TBL] [Abstract][Full Text] [Related]
47. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Campbell JI; Yau C; Krass P; Moore D; Carey LA; Au A; Chhieng D; Giri D; Livasy C; Mies C; Rabban J; Sarode VR; Singh B; Esserman L; Chen YY
Breast Cancer Res Treat; 2017 Aug; 165(1):181-191. PubMed ID: 28577078
[TBL] [Abstract][Full Text] [Related]
48. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only.
de Vries RR; Nieuwenhuijzen JA; Meinhardt W; Bais EM; Horenblas S
Eur J Surg Oncol; 2009 Apr; 35(4):352-5. PubMed ID: 18722076
[TBL] [Abstract][Full Text] [Related]
49. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
Fisher B; Jeong JH; Anderson S; Wolmark N
J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
[TBL] [Abstract][Full Text] [Related]
50. Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer.
Cockburn A; Yan J; Rahardja D; Euhus D; Peng Y; Fang Y; Rumnong Sarode V
Hum Pathol; 2014 Feb; 45(2):249-58. PubMed ID: 24289969
[TBL] [Abstract][Full Text] [Related]
51. Examination of Tumor Regression Grading Systems in Breast Cancer Patients Who Received Neoadjuvant Therapy.
Sejben A; Kószó R; Kahán Z; Cserni G; Zombori T
Pathol Oncol Res; 2020 Oct; 26(4):2747-2754. PubMed ID: 32691390
[TBL] [Abstract][Full Text] [Related]
52. Characterization and clinical impact of residual disease after neoadjuvant chemotherapy.
Viale G
Breast; 2013 Aug; 22 Suppl 2():S88-91. PubMed ID: 24074800
[TBL] [Abstract][Full Text] [Related]
53. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
Promberger R; Dubsky P; Mittlböck M; Ott J; Singer C; Seemann R; Exner R; Panhofer P; Steger G; Bergen E; Gnant M; Jakesz R; Bago-Horvath Z; Rudas M; Bartsch R
Clin Breast Cancer; 2015 Dec; 15(6):505-11. PubMed ID: 26195436
[TBL] [Abstract][Full Text] [Related]
54. The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer.
Teleki I; Krenacs T; Szasz MA; Kulka J; Wichmann B; Leo C; Papassotiropoulos B; Riemenschnitter C; Moch H; Varga Z
BMC Cancer; 2013 Feb; 13():50. PubMed ID: 23374644
[TBL] [Abstract][Full Text] [Related]
55. Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients.
Romero A; García-Sáenz JA; Fuentes-Ferrer M; López Garcia-Asenjo JA; Furió V; Román JM; Moreno A; de la Hoya M; Díaz-Rubio E; Martín M; Caldés T
Ann Oncol; 2013 Mar; 24(3):655-61. PubMed ID: 23104719
[TBL] [Abstract][Full Text] [Related]
56. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
Mohapatra M; Sarma YS
J Cancer Res Ther; 2020; 16(6):1419-1425. PubMed ID: 33342807
[TBL] [Abstract][Full Text] [Related]
57. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.
Cho N; Im SA; Park IA; Lee KH; Li M; Han W; Noh DY; Moon WK
Radiology; 2014 Aug; 272(2):385-96. PubMed ID: 24738612
[TBL] [Abstract][Full Text] [Related]
58. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
Chagpar AB; Middleton LP; Sahin AA; Dempsey P; Buzdar AU; Mirza AN; Ames FC; Babiera GV; Feig BW; Hunt KK; Kuerer HM; Meric-Bernstam F; Ross MI; Singletary SE
Ann Surg; 2006 Feb; 243(2):257-64. PubMed ID: 16432360
[TBL] [Abstract][Full Text] [Related]
59. Histopathologic changes following neoadjuvant chemotherapy in locally advanced breast cancer.
Sethi D; Sen R; Parshad S; Khetarpal S; Garg M; Sen J
Indian J Cancer; 2013; 50(1):58-64. PubMed ID: 23713048
[TBL] [Abstract][Full Text] [Related]
60. [Factors related with pathological complete response of neoadjuvant chemotherapy in primary breast cancer].
Cheng YJ; Ye JM; Xu L; Zhao JX; Duan XN; Liu YH
Zhonghua Wai Ke Za Zhi; 2013 Apr; 51(4):339-43. PubMed ID: 23895756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
